Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Biosimilars Market’s Growth Trajectory From 2025 To 2034?

In recent times, the biosimilars market has seen a sharp increase in size. The market value, which is predicted to shift from $18.65 billion in 2024 to $21.85 billion in 2025, will exhibit a compound annual growth rate (CAGR) of 17.2%. This notable growth in the historical period is due to various factors, namely, a rise in cancer cases, significant economic development in budding markets, an escalade in the expenditure for pharmaceutical R&D, expanded healthcare funding, increasing governmental initiatives, a robust drug pipeline, diminutive cost of biosimilars, and a surge in patent expirations.

The biosimilars market is projected to experience rapid expansion in the coming years, escalating to $41.34 billion in 2029 with a compound annual growth rate (CAGR) of 17.3%. Various factors contributing to this anticipated growth in the forecast period include the rising incidence of cancer, escalating demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), growth in healthcare spending, increased potential in upcoming economies, advances in technology, the growing influence of biological drugs, the aging demographic, and enhanced healthcare access. In the forecast period, significant trends include heightened emphasis on rigorous R&D for the creation of innovative and potent drugs, a focus on mergers and acquisitions as a growth plan, efforts towards forming strategic alliances, increased investment, and a shift towards integrating artificial intelligence.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Are the Core Market Drivers Propelling Growth in the Biosimilars Industry?

The escalating prevalence of chronic illnesses such as arthritis, asthma, and cancer is anticipated to be a primary driving force for the biosimilars market. Factors contributing to the rise in chronic diseases include extended work hours, limited physical exercise, along with unhealthy dietary and drinking choices, and biosimilars are increasingly becoming a common treatment method for such diseases. They work by initiating the immune system’s response against cancer cells, assisting the body in eradicating the cancer cells. A United Nations piece suggests that by 2030, chronic diseases are expected to cause 70% of all global deaths. Furthermore, the worldwide impact of chronic disease is predicted to reach approximately 60%. Hence, the upward trend in chronic diseases is likely to fuel the demand for biosimilars, subsequently advancing the biosimilars market.

How Is the Biosimilars Market Segmented?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Which Regions Are Driving the Next Phase of the Biosimilars Market Growth?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Market Trends and Innovations Are Shaping the Future of the Biosimilars Industry?

In an effort to establish a competitive presence in the biosimilars market, leading companies are centred on the creation of novel products. More than a million patients with certain severe inflammatory illnesses rely on Humira, and AMJEVITA is the first biosimilar to this medication in the U.S. For instance, Amgen Inc., a biotechnology company based in the U.S., introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), in the U.S. in January 2023. AMJEVITA (40 mg) is been offered at a wholesale acquisition cost, which is 55% lower than the existing Humira’s list price. It’s also provided with a 5% reduction on the existing list price of Humira.

View the full report here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

How Is the Biosimilars Market Defined and What Are Its Core Parameters?

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model